Clinical potential of the mTOR targets S 6 K 1 and S 6 K 2 in breast cancer

Aim: The Mammalian Target of Rapamycin (mTOR) and its substrates S6K1 and S6K2 regulate cell growth, proliferation and metabolism through translational control. RPS6KB1 (S6K1) and RPS6KB2 (S6K2) are situated in the commonly amplified 17q21-23 and 11q13 regions. S6K1 amplification and protein overexpression have earlier been associated with a worse outcome in breast cancer, but information regarding S6K2 is scarce. The aim of this study was to evaluate the prognostic and treatment predictive relevance of S6K1/S6K2 gene amplification, as well as S6K2 protein expression in breast cancer. Material & Methods: S6K1/S6K2 gene copy number was determined by real-time PCR in 207 stage II breast tumors and S6K2 protein expression was investigated by immunohistochemistry in 792 node-negative breast cancers. Results: S6K1 amplification/gain was detected in 10.7%/21.4% and S6K2 amplification/gain in 4.3%/21.3% of the tumors. S6K2 protein was detected in the nucleus (38%) and cytoplasm (76%) of the tumor cells. S6K1 amplification was significantly associated with HER2 gene amplification and protein expression. S6K2 amplification correlated significantly with high S6K2 mRNA levels, ER+ status and CCND1 amplification. S6K1 and S6K2 gene amplification was associated with a worse prognosis independent of HER2 and CCND1. S6K2 gain and nuclear S6K2 expression was related to an improved benefit from tamoxifen among patients with ER+ respectively ER+/PgR+ tumors. In the ER+/PgRsubgroup, nuclear S6K2 rather indicated decreased tamoxifen responsiveness. S6K1 amplification predicted reduced benefit from radiotherapy. Conclusions: This is the first study showing that S6K2 amplification and overexpression, like S6K1 amplification, have prognostic and treatment predictive significance in breast cancer.

[1]  L. Skoog,et al.  Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients , 2004, Acta oncologica.

[2]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[3]  M. J. van de Vijver,et al.  Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients , 2004, British Journal of Cancer.

[4]  W. Sauerbrei,et al.  REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.

[5]  T. Ohnishi,et al.  In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. , 1998, Biochemical and biophysical research communications.

[6]  Olle Stål,et al.  Akt kinases in breast cancer and the results of adjuvant therapy , 2003, Breast Cancer Research.

[7]  L. Skoog,et al.  c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. , 1995, European journal of cancer.

[8]  Stefano Fumagalli,et al.  Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase , 1998, The EMBO journal.

[9]  T. Singleton,et al.  Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. , 1992, Pathology annual.

[10]  Hyun-Ah Kim,et al.  Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables , 2008, Breast Cancer Research and Treatment.

[11]  M. Holz,et al.  S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation* , 2009, Journal of Biological Chemistry.

[12]  K. Camphausen,et al.  Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. , 2003, Cancer research.

[13]  Simak Ali,et al.  Phosphorylation of Estrogen Receptor-α at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer Patients , 2007, Clinical Cancer Research.

[14]  J. Blenis,et al.  Characterization of S6K2, a novel kinase homologous to S6K1 , 1999, Oncogene.

[15]  D. Albertson,et al.  Gene amplification in cancer. , 2006, Trends in genetics : TIG.

[16]  H. Yamashita,et al.  Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer , 2005, Breast Cancer Research.

[17]  W. Gullick,et al.  c-erbB2 amplification and overexpression in human tumors. , 1992, Cancer treatment and research.

[18]  In-Hyun Park,et al.  Regulation of Ribosomal S6 Kinase 2 by Mammalian Target of Rapamycin* , 2002, The Journal of Biological Chemistry.

[19]  Wolfgang Eiermann,et al.  Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. Skoog,et al.  PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer , 2007, Clinical Cancer Research.

[21]  L. Skoog,et al.  Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer , 2007, Oncogene.

[22]  R. Pearson,et al.  Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function , 2007, Growth factors.

[23]  R. Greil,et al.  Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  H. Johansson,et al.  Long-term follow-up of the Stockholm randomized trials of postoperative radiation therapy versus adjuvant chemotherapy among ‘high risk’ pre- and postmenopausal breast cancer patients , 2006, Acta oncologica.

[25]  Shiuan Chen,et al.  The molecular basis of the interaction between the proline-rich SH3-binding motif of PNRC and estrogen receptor alpha , 2006, Nucleic acids research.

[26]  Stefano Fumagalli,et al.  S6K1−/−/S6K2−/− Mice Exhibit Perinatal Lethality and Rapamycin-Sensitive 5′-Terminal Oligopyrimidine mRNA Translation and Reveal a Mitogen-Activated Protein Kinase-Dependent S6 Kinase Pathway , 2004, Molecular and Cellular Biology.

[27]  Andrew R. Green,et al.  CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.

[28]  R. Schiff,et al.  Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities , 2007, Clinical Cancer Research.

[29]  T. Ohnishi,et al.  Antisense inhibition of the RAD51 enhances radiosensitivity. , 1996, Biochemical and biophysical research communications.

[30]  I. Bièche,et al.  Novel approach to quantitative polymerase chain reaction using real‐time detection: Application to the detection of gene amplification in breast cancer , 1998, International journal of cancer.

[31]  Fergus J. Couch,et al.  The 17q23 Amplicon and Breast Cancer , 2003, Breast Cancer Research and Treatment.

[32]  O. Stål,et al.  Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells. , 2005, International journal of oncology.

[33]  H. Johansson,et al.  Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer , 2007, Acta oncologica.

[34]  Manuel Hidalgo,et al.  Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity , 2004, Clinical Cancer Research.

[35]  E. Hafen,et al.  Drosophila S6 kinase: a regulator of cell size. , 1999, Science.

[36]  F. Couch,et al.  Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. , 1999, Cancer research.

[37]  K. Ang,et al.  Sensitization of breast cancer cells to radiation by trastuzumab. , 2003, Molecular cancer therapeutics.

[38]  D. Kupferwasser,et al.  Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1. , 2003, The Biochemical journal.

[39]  L. Skoog,et al.  Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients , 2009, Clinical Cancer Research.

[40]  J. Blenis,et al.  Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.

[41]  Hanina Hibshoosh,et al.  PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. , 2005, Cancer research.

[42]  Jiang Shou,et al.  Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.

[43]  Shiuan Chen,et al.  Dual Inhibition of mTOR and Estrogen Receptor Signaling In vitro Induces Cell Death in Models of Breast Cancer , 2005, Clinical Cancer Research.

[44]  L. Skoog,et al.  The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  H. Kurokawa,et al.  ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[47]  Valeriy Filonenko,et al.  Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer. , 2005, Experimental oncology.

[48]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[49]  Peter Schraml,et al.  Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer , 2004, Cancer Research.

[50]  K. Jirström,et al.  Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. , 2005, Cancer research.

[51]  D. Birnbaum,et al.  BMC Cancer , 2003 .